ACADIA to Host Conference Call and Webcast on Wednesday, May 10, 2006, at 5:00 p.m. Eastern Time
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2006 on Wednesday, May 10, 2006, after the U.S. financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, Vice President and Chief Financial Officer, will host a conference call and webcast on Wednesday, May 10, 2006 at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and provide an update on the company's development programs.
The conference call may be accessed by dialing 866-713-8395 for participants in the U.S. or Canada and 617-597-5309 for international callers (reference passcode 76699715). A telephone replay of the conference call may be accessed through May 24, 2006 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 24798056). The conference call also will be webcast live on ACADIA's website, http://www.acadia-pharm.com/, under the investors section and will be archived there until May 24, 2006.
About ACADIA Pharmaceuticals ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five Phase II-stage clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
Contacts:
ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871
DATASOURCE: ACADIA Pharmaceuticals Inc.
CONTACT: Lisa Barthelemy, Director, Investor Relations, or Thomas H.
Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871 Web site: http://www.acadia-pharm.com/
|